Progress on pharmacogenetics of pediatric inflammatory bowel disease
10.3760/cma.j.issn.1673-4408.2025.10.011
- VernacularTitle:儿童炎症性肠病药物遗传学研究进展
- Author:
Huifang YANG
1
;
Zhantu LIANG
Author Information
1. 中山市博爱医院儿童消化科 528403
- Keywords:
Children;
Inflammatory bowel disease;
Pharmacogenetics
- From:
International Journal of Pediatrics
2025;52(10):698-702
- CountryChina
- Language:Chinese
-
Abstract:
The pathogenesis of pediatric inflammatory bowel disease（IBD）is complex，and there is currently no cure. Pharmacotherapy is the primary treatment approach for pediatric IBD at present，with commonly used medications including 5-aminosalicylates，glucocorticoids，immunosuppressive agents and biologics. During treatment，primary or secondary non-response to medications or adverse drug reactions often necessitate discontinuation of related drugs. Pharmacogenetics can predict drug efficacy and reduce adverse drug reactions，palying a particularly important role in assisting treatment of pediatric IBD. This article reviews recent pharmacogenetic research progress on pediatric IBD，exploring drug responses across different genetic backgrounds，to provide a reference for individualized precision therapy in pediatric IBD.
